Coming Soon: Conexiant’s news site is becoming MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more.
Ophthalmology
Partner With Us
Advertisement
Conexiant chevron_right Ophthalmology chevron_right The Next Generation of VEGF Inhibition with VEGF-C and VEGF-D
From the Journals

The Next Generation of VEGF Inhibition with VEGF-C and VEGF-D

“Combination inhibition of extracellular ligands VEGF-A, VEGF-C, and VEGF-D, and/or intracellular blockade of VEGF receptor signaling, which has been successfully applied in oncology, also may hold promise for addressing some current challenges of nAMD management.”

MDSpire News
5 Key Takeaways

  • 1

    VEGF-C and VEGF-D are explored as alternatives to VEGF-A in treating neovascular macular degeneration and other retinal diseases.

  • 2

    VEGF-C and VEGF-D signaling pathways are significant in the pathogenesis of tumors and retinal diseases, alongside VEGF-A.

  • 3

    Current treatments for retinal diseases primarily target VEGF-A, but compensatory upregulation of VEGF-C and VEGF-D may limit efficacy.

  • 4

    A clinical development 'trap' inhibitor of VEGF-C and VEGF-D aims to enhance treatment outcomes by preventing angiogenesis and vascular leakage.

  • 5

    Research indicates that broader inhibition of VEGF family members may improve management of neovascular macular degeneration.

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.